Angelman Biomarkers and Outcome Measures Alliance and Roche begin patient-centered qualitative research to inform potential outcome measures for Angelman syndrome clinical trials
F. Hoffmann-La Roche Ltd, (Roche), one of the world’s largest pharmaceutical and diagnostics companies, announced today that it has funded the first phase of a study to better understand which symptoms of Angelman syndrome impact families most. The study aims to better understand the impact of Angelman syndrome on patients and their families through interviews with caregivers and physicians around the world. Roche is partnering with the Angelman Biomarkers and Outcome Measures Alliance (A-BOM) on the study. ASF and FAST joined efforts with Agilis Biopharmaceuticals to create A-BOM in 2016. A-BOM works collaboratively to develop testing and evaluation tools for individuals with AS for future clinical trials. Read more.